[go: up one dir, main page]

SG11202004801WA - A conjugate of a tubulysin analog with branched linkers - Google Patents

A conjugate of a tubulysin analog with branched linkers

Info

Publication number
SG11202004801WA
SG11202004801WA SG11202004801WA SG11202004801WA SG11202004801WA SG 11202004801W A SG11202004801W A SG 11202004801WA SG 11202004801W A SG11202004801W A SG 11202004801WA SG 11202004801W A SG11202004801W A SG 11202004801WA SG 11202004801W A SG11202004801W A SG 11202004801WA
Authority
SG
Singapore
Prior art keywords
conjugate
branched linkers
tubulysin analog
tubulysin
analog
Prior art date
Application number
SG11202004801WA
Inventor
Robert Yongxin Zhao
Qingliang Yang
Yuanyuan Huang
Linyao Zhao
Shun Gai
Hangbo Ye
Jun Lei
Yifang Xu
Mingjun Cao
Huihui Guo
Junxiang Jia
Qianqian Tong
Wenjun Li
Xiaomai Zhou
Hongsheng Xie
Lu Bai
Xiang Cai
Xiaotao Zhuo
Xiuzheng Zhang
Jun Zheng
Original Assignee
Hangzhou Dac Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Dac Biotech Co Ltd filed Critical Hangzhou Dac Biotech Co Ltd
Publication of SG11202004801WA publication Critical patent/SG11202004801WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202004801WA 2017-12-31 2017-12-31 A conjugate of a tubulysin analog with branched linkers SG11202004801WA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/120454 WO2019127607A1 (en) 2017-12-31 2017-12-31 A conjugate of a tubulysin analog with branched linkers

Publications (1)

Publication Number Publication Date
SG11202004801WA true SG11202004801WA (en) 2020-06-29

Family

ID=67064953

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202004801WA SG11202004801WA (en) 2017-12-31 2017-12-31 A conjugate of a tubulysin analog with branched linkers

Country Status (16)

Country Link
US (4) US11998584B2 (en)
EP (1) EP3621652A4 (en)
JP (2) JP7262817B2 (en)
KR (2) KR102603344B1 (en)
CN (1) CN111093707A (en)
AU (2) AU2017445144A1 (en)
BR (1) BR112020010405A2 (en)
CA (1) CA3085634C (en)
CL (1) CL2020001600A1 (en)
EA (1) EA202091217A1 (en)
IL (2) IL317268A (en)
MX (1) MX2020006192A (en)
PH (1) PH12020550657A1 (en)
SG (1) SG11202004801WA (en)
WO (1) WO2019127607A1 (en)
ZA (1) ZA202003211B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11873281B2 (en) 2012-07-12 2024-01-16 Hangzhou Dac Biotech Co., Ltd. Conjugates of cell binding molecules with cytotoxic agents
EP3348280A1 (en) 2012-07-12 2018-07-18 Hangzhou Dac Biotech Co., Ltd Conjugates of cell binding molecules with cytotoxic agents
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
IL317268A (en) * 2017-12-31 2025-01-01 Hangzhou Dac Biotech Co Ltd A conjugate of a tubulysin analog with branched linkers
CA3124106A1 (en) 2018-12-21 2020-06-25 Regeneron Pharmaceuticals, Inc. Tubulysins and protein-tubulysin conjugates
PH12021500050A1 (en) * 2019-06-24 2022-05-02 Hangzhou Dac Biotech Co Ltd A conjugate of a cytotoxic agent to a cell binding molecule with branched linkers
SG11202113022UA (en) * 2019-06-24 2021-12-30 Hangzhou Dac Biotech Co Ltd A formulation of a conjugate of a tubulysin analog to a cell-binding molecule
EP3991752A4 (en) * 2019-06-29 2023-03-29 Hangzhou Dac Biotech Co., Ltd Cell-binding molecule-tubulysin derivative conjugate and preparation method therefor
SG11202101719PA (en) * 2019-08-07 2021-03-30 Mabplex International Co Ltd Antibody-drug conjugate and application thereof
MX2022007353A (en) 2019-12-17 2022-09-19 Univ Texas NOVEL DDR1 ANTIBODIES AND THEIR USES.
CA3108168A1 (en) * 2020-02-05 2021-08-05 Yue Zhang Conjugates of cell-binding molecules with cytotoxic agents
US11045546B1 (en) 2020-03-30 2021-06-29 Cytodyn Inc. Methods of treating coronavirus infection
US20230159450A1 (en) * 2020-05-08 2023-05-25 The Feinstein Institutes For Medical Research Dimers for use in synthesis of peptidomimetics
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
CN112138170B (en) * 2020-09-28 2022-05-20 广东药科大学 Conjugate for preventing cisplatin drug-induced deafness and preparation method and application thereof
CN112755173B (en) * 2020-12-31 2022-01-07 深圳市科达顺生物技术有限公司 Ii-Key/HER2 hybrid polypeptide medicine for treating triple negative breast cancer and preparation method thereof
CN112961060B (en) * 2021-02-09 2022-03-25 武汉大学 Isotope labeled N, N-dimethylethylenediamine, preparation method thereof and analysis method of short-chain fatty acid
AU2022259314A1 (en) 2021-04-14 2023-11-30 Genequantum Healthcare (Suzhou) Co., Ltd. Linkers, conjugates and applications thereof
EP4355366A4 (en) * 2021-06-16 2025-05-07 Fusion Pharmaceuticals Inc. COMBINATION COMPRISING A NEUROTENSIN RECEPTOR BINDING COMPOUND AND NAPOLI
CA3231134A1 (en) * 2021-09-08 2023-03-16 Coherent Biopharma (Suzhou) Limited Pharmaceutical preparation, preparation method therefor and use thereof
EP4426727A2 (en) * 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
EP4514336A1 (en) * 2022-04-28 2025-03-05 Scirosbio (FZC) Compositions and methods for treatment of cancer
WO2023244803A1 (en) * 2022-06-17 2023-12-21 The Regents Of The University Of California Methods and compositions comprising tobacco mild green mosaic virus (tmgmv)
WO2024239281A1 (en) * 2023-05-24 2024-11-28 Hangzhou Seehe Biotechnology Co., Ltd Targeted treatment of prostate cancers and other tumors by an antibody-drug conjugate
WO2025021118A1 (en) * 2023-07-25 2025-01-30 海南先声再明医药股份有限公司 Ligand-drug conjugate and linker for conjugation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776814B2 (en) 2002-07-09 2010-08-17 R&D-Biopharmaceuticals Gmbh Tubulysin conjugates
CA2680535C (en) 2007-03-14 2016-09-20 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
EP3348280A1 (en) * 2012-07-12 2018-07-18 Hangzhou Dac Biotech Co., Ltd Conjugates of cell binding molecules with cytotoxic agents
ES2701076T3 (en) * 2012-11-24 2019-02-20 Hangzhou Dac Biotech Co Ltd Hydrophilic linkers and their uses for the conjugation of drugs to molecules that bind to cells
GB201402009D0 (en) * 2014-02-06 2014-03-26 Oncomatryx Biopharma S L Antibody-drug conjugates and immunotoxins
CA2938919C (en) 2014-02-28 2020-12-29 Hangzhou Dac Biotech Co., Ltd Charged linkers and their uses for conjugation
EP3129362A4 (en) * 2014-04-11 2017-08-23 Medimmune, LLC Tubulysin derivatives
US20170290878A1 (en) 2014-09-25 2017-10-12 Endocyte, Inc. Methods of treating cancer with tubulysin conjugates
CN110279872A (en) * 2014-11-11 2019-09-27 杭州多禧生物科技有限公司 Conjugated body of the cytotoxic molecule with cell bound receptor molecule
WO2015151078A2 (en) * 2015-06-15 2015-10-08 Suzhou M-Conj Biotech Co., Ltd Hydrophilic linkers for conjugation
JP6817288B2 (en) * 2015-08-10 2021-01-20 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． Its use in novel conjugates and specific conjugation of biomolecules with drugs
EP3411074A4 (en) * 2016-02-04 2019-09-04 Suzhou M-conj Biotech Co., Ltd. Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
NZ744936A (en) * 2016-04-20 2022-01-28 Hangzhou Dac Biotech Co Ltd Derivatives of amanita toxins and their conjugation to a cell binding molecule
WO2018086139A1 (en) * 2016-11-14 2018-05-17 Hangzhou Dac Biotech Co., Ltd Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
KR102655301B1 (en) 2017-04-06 2024-04-08 항저우 디에이씨 바이오테크 씨오, 엘티디 Conjugation of a cytotoxic drug with bis-linkage
IL317268A (en) * 2017-12-31 2025-01-01 Hangzhou Dac Biotech Co Ltd A conjugate of a tubulysin analog with branched linkers

Also Published As

Publication number Publication date
CN111093707A (en) 2020-05-01
IL275274B1 (en) 2025-01-01
US11998584B2 (en) 2024-06-04
AU2022205269B2 (en) 2024-07-11
KR20200097295A (en) 2020-08-18
IL317268A (en) 2025-01-01
IL275274B2 (en) 2025-05-01
ZA202003211B (en) 2024-04-24
PH12020550657A1 (en) 2021-04-19
US20230165930A1 (en) 2023-06-01
EP3621652A4 (en) 2021-01-13
JP2021507928A (en) 2021-02-25
KR102603344B1 (en) 2023-11-16
AU2022205269A1 (en) 2022-08-11
CA3085634A1 (en) 2019-07-04
NZ764814A (en) 2024-02-23
AU2017445144A1 (en) 2020-06-18
KR102641565B1 (en) 2024-02-27
CL2020001600A1 (en) 2021-03-19
US20230165931A1 (en) 2023-06-01
BR112020010405A2 (en) 2020-11-24
CA3085634C (en) 2023-11-14
IL275274A (en) 2020-07-30
JP2023093531A (en) 2023-07-04
EP3621652A1 (en) 2020-03-18
JP7262817B2 (en) 2023-04-24
MX2020006192A (en) 2020-08-20
WO2019127607A1 (en) 2019-07-04
JP7637431B2 (en) 2025-02-28
EA202091217A1 (en) 2020-09-18
KR20230075530A (en) 2023-05-31
US20200276261A1 (en) 2020-09-03
US20230149502A1 (en) 2023-05-18

Similar Documents

Publication Publication Date Title
IL275274A (en) A conjugate of a tubulysin analog with branched linkers
IL269713A (en) Conjugation of a cytotoxic drug with bis-linkage
IL273471A (en) Antibody-pyrrolobenzodiazepine derivative conjugate
ZA202003833B (en) Conjugates and preparation and use thereof
IL266310A (en) Peptide-containing linkers for antibody-drug conjugates
SI3592393T1 (en) Releasable conjugates
SI3794042T1 (en) Anti-muc1- exatecan antibody-drug conjugate
SG11202007919RA (en) Antibody-drug conjugate having acidic self-stabilization junction
EP3501548A4 (en) Tissue factor-targeted antibody-drug conjugate
IL254258A0 (en) Cryptophycin-based antibody-drug conjugates with novel self-immolative linkers
SG11202104993SA (en) Anti-cdh6 antibody-pyrrolobenzodiazepine derivative conjugate
EP3668838A4 (en) Tetramaleimide linkers and use thereof
PL3271329T3 (en) Novel hydrophilic linkers and ligand-drug conjugates thereof
SG10202109376YA (en) Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof
SG11202106658XA (en) Rifamycin analogs and antibody-drug conjugates thereof
IL283682A (en) Linkers
IL269321A (en) Drug-polymer conjugate
ES2974288T9 (en) Antibody-drug conjugates including hemiasterlin derivative
PL3566674T3 (en) Digitizable dental implant analog
EP3856258C0 (en) Sulfomaleimide-based linkers and corresponding conjugates
GB201710097D0 (en) A sensitizer - peptide conjugate
GB201713700D0 (en) Peptide conjugates
HK40015876A (en) A conjugate of a tubulysin analog with branched linkers
IL271968A (en) Adjustable vascular ring and implantable kit comprising such a ring
IL271741A (en) Pro-drug peptide with improved pharmaceutical properties